ResearchDx Hires New Staff to Senior Management Team

Research Dx is pleased to announce two new additions to the senior management team. Stephen Jones as Chief Operating Officer and Tom Li as VP Business Development. Stephen Jones Chief Operating Officer  Steve Jones is the COO for ResearchDx responsible for end-to-end oversight of all functions including laboratory operations, business development and research and development. Prior […]

Read More

INOVIQ (ASX:IIQ) Partners with ResearchDx to Develop SubB2M-Based Cancer Tests in the US

Originally sourced from CMOCRO   INOVIQ (IIQ) signs a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the […]

Read More

PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth

Originally sourced from Business Wire   NEW YORK–(BUSINESS WIRE)–Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that a new, wholly owned subsidiary of Lucid, LucidDx Labs Inc. (“LucidDx Labs”) has acquired from ResearchDx, Inc. (“RDx”), a CLIA-certified, CAP-accredited […]

Read More